| Generalized Anxiety Disorder
Xanax vs Effexor XR
Side-by-side clinical, coverage, and cost comparison for generalized anxiety disorder.Deep comparison between: Xanax vs Effexor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEffexor has a higher rate of injection site reactions vs Xanax based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Effexor but not Xanax, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xanax
Effexor
At A Glance
Oral
Three times daily
Benzodiazepine
Oral
Daily
SNRI
Indications
- Generalized Anxiety Disorder
- Major Depressive Disorder
- Generalized Anxiety Disorder
- Phobia, Social
- Panic Disorder
Dosing
Generalized Anxiety Disorder Starting oral dose 0.25 mg to 0.5 mg three times daily; may increase every 3 to 4 days to a maximum of 4 mg daily in divided doses; use the lowest effective dose.
Panic Disorder Starting oral dose 0.5 mg three times daily; may increase every 3 to 4 days by no more than 1 mg per day; controlled trials used 1 mg to 10 mg daily (mean approximately 5 mg to 6 mg daily); reassess periodically when doses exceed 4 mg per day.
Geriatric Patients Starting oral dose 0.25 mg two or three times daily; increase gradually if needed and tolerated.
Hepatic Impairment Starting oral dose 0.25 mg two or three times daily; increase gradually if needed and tolerated.
Major Depressive Disorder Starting dose 37.5-75 mg/day; target 75 mg/day; max 225 mg/day; administered once daily with food.
Generalized Anxiety Disorder Starting dose 37.5-75 mg/day; target 75 mg/day; max 225 mg/day; administered once daily with food.
Phobia, Social Recommended dose 75 mg/day; administered once daily with food; no evidence that higher doses confer additional benefit.
Panic Disorder Starting dose 37.5 mg/day for 7 days, then 75 mg/day; max 225 mg/day; administered once daily with food.
Contraindications
- Known hypersensitivity to alprazolam or other benzodiazepines (angioedema reported)
- Concomitant use of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole), except ritonavir
- Known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate, or any excipients in the formulation
- Concomitant use with MAOIs (including linezolid and intravenous methylene blue), or within 14 days of stopping an MAOI antidepressant, due to risk of serotonin syndrome
Adverse Reactions
Most common (>=1%) Drowsiness, light-headedness, impaired coordination, memory impairment, irritability, cognitive disorder, dry mouth, constipation, decreased libido, weight gain
Serious Respiratory depression with concomitant opioids, dependence and withdrawal reactions, withdrawal seizures, paradoxical reactions (agitation, rage, hostility), hepatitis, hepatic failure
Postmarketing Hyperprolactinemia, peripheral edema, hypomania, mania, gynecomastia, galactorrhea, photosensitivity reaction, angioedema, Stevens-Johnson syndrome
Most common (>=5%) Nausea, somnolence, dry mouth, sweating, abnormal ejaculation, anorexia, constipation, impotence, decreased libido
Serious Serotonin syndrome, elevated blood pressure, increased risk of bleeding, angle-closure glaucoma, activation of mania/hypomania, discontinuation syndrome, seizure, hyponatremia, interstitial lung disease, eosinophilic pneumonia
Postmarketing Anaphylaxis, angioedema, QT prolongation, ventricular fibrillation, ventricular tachycardia (including torsade de pointes), takotsubo cardiomyopathy, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, neuroleptic malignant syndrome, rhabdomyolysis, hyponatremia, SIADH
Pharmacology
Alprazolam is a 1,4 benzodiazepine that binds to the benzodiazepine site of GABA-A receptors in the brain, enhancing GABA-mediated synaptic inhibition to produce anxiolytic and antipanic effects.
Venlafaxine is an SNRI whose antidepressant and anxiolytic effects are thought to be related to potentiation of serotonin and norepinephrine in the CNS through inhibition of their reuptake; it also weakly inhibits dopamine reuptake and has no significant affinity for muscarinic, H1-histaminergic, or alpha1-adrenergic receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xanax
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Effexor
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Xanax
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (4/8)
Effexor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xanax
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Effexor
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xanax.
No savings programs available for Effexor.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EffexorView full Effexor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.